A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
about
Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.
P2860
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@ast
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@en
type
label
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@ast
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@en
prefLabel
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@ast
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@en
P2093
P2860
P1433
P1476
A Novel Bispecific Antibody ag ...... A10 for Breast Cancer Therapy.
@en
P2093
Haruhiko Kamada
Kazuma Higashisaka
Kazuya Nagano
Masaki Inoue
Shintaro Taki
Yasuo Tsutsumi
Yasuo Yoshioka
Yohei Mukai
P2860
P304
P356
10.1371/JOURNAL.PONE.0144712
P407
P577
2015-12-17T00:00:00Z